Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LAWRENCEVILLE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018...
-
LAWRENCEVILLE, N.J., June 25, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index...
-
Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies Supported with Solid Fundamentals and a Strong Balance Sheet Company to Hold Conference...
-
LAWRENCEVILLE, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will...
-
LAWRENCEVILLE, N.J., May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
-
LAWRENCEVILLE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®,...
-
Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted Symposium, “Emerging...
-
Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT ...
-
LAWRENCEVILLE, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year...
-
LAWRENCEVILLE, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman,...